Payment overview · 2025
General Payments
$153.57
6 reported records · 6 companies
Healthcare provider profile · identity verified
Usha Agarwal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TRINITY, FL · NPI 1427043421
Verified facts
What the public records show
CMS Open Payments records show Usha Agarwal, MD received $153.57 in general payments during 2025 across 6 reported records.
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $60.94 | 39.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.00 | 14.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.69 | 12.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.14 | 12.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.30 | 11.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.50 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $153.57 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $60.94 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 31 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 688 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 102 |
| Lisinopril | Lisinopril | 316 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 30 |
| Losartan Potassium | Losartan Potassium | 186 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 181 | 56 |
| Metformin Hcl | Metformin Hcl | 177 | 55 |
| Omeprazole | Omeprazole | 175 | 53 |
| Ezetimibe | Ezetimibe | 164 | 44 |
| Januvia | Sitagliptin Phosphate | 159 | 29 |
| Gabapentin | Gabapentin | 153 | 45 |
| Alprazolam | Alprazolam | 146 | 34 |
| Furosemide | Furosemide | 137 | 34 |
| Alendronate Sodium | Alendronate Sodium | 132 | 45 |
| Trazodone Hcl | Trazodone Hcl | 131 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 17 |
| Glimepiride | Glimepiride | 109 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 43 |
| Fenofibrate | Fenofibrate | 97 | 23 |
| Carvedilol | Carvedilol | 94 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 30 |
| Simvastatin | Simvastatin | 87 | 31 |
| Sertraline Hcl | Sertraline Hcl | 86 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 26 |
| Tramadol Hcl | Tramadol Hcl | 80 | 25 |
| Lorazepam | Lorazepam | 72 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 15 |
| Allopurinol | Allopurinol | 56 | 14 |
| Ibuprofen | Ibuprofen | 54 | 14 |
| Glipizide | Glipizide | 53 | 14 |
| Atenolol | Atenolol | 52 | 17 |
| Meclizine Hcl | Meclizine Hcl | 52 | 15 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 12 |
| Famotidine | Famotidine | 48 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | suppressed |
| Potassium Chloride | Potassium Chloride | 47 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | suppressed |
| Temazepam | Temazepam | 46 | suppressed |
| Lovastatin | Lovastatin | 43 | 13 |
| Meloxicam | Meloxicam | 42 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 13 |
| Montelukast Sodium | Montelukast Sodium | 41 | 16 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 40 | suppressed |
| Nifedipine Er | Nifedipine | 40 | 11 |
| Spironolactone | Spironolactone | 40 | 13 |
| Clonidine Hcl | Clonidine Hcl | 39 | 11 |
| Methylprednisolone | Methylprednisolone | 39 | 35 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 13 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 14 |
| Acyclovir | Acyclovir | 31 | suppressed |
| Eliquis | Apixaban | 31 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 12 |
| Nystatin | Nystatin | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 22 |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 17 |
| Breyna | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | 12 |
| Cilostazol | Cilostazol | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 13 |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Ozempic | Semaglutide | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $153.57 · 6 records | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | ELIQUIS, LifeVest, NURTEC ODT, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error